Physician profile
Brian A Bui
NPI 1013957125
$6,021.33
in general payments reported to CMS, 2019-2025
34 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $229 · 2022: $888 · 2023: $1,474 · 2024: $1,739 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $848.69 | 2019-2025 | |
| Medtronic, INC. | $710.10 | 2023-2025 | Linq II, Symplicity G3, Onyx Frontier |
| Scpharmaceuticals INC. | $550.93 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $491.73 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $470.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.63 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $297.04 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals, Ltd. | $223.14 | 2022-2023 | Arcalyst |
| Novo Nordisk INC | $213.49 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $208.35 | 2022-2023 | Verquvo |
| Abbott Laboratories | $174.67 | 2020-2024 | Cardiomems, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals Lp | $161.39 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $156.16 | 2019-2024 | |
| Cvrx, INC. | $147.74 | 2022-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.88 | 2019-2025 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $130.64 | 2024 | Arcalyst |
| Amgen INC. | $122.24 | 2019-2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $63.13 | 2023-2024 | Inpefa |
| Philips North America LLC | $59.58 | 2022-2024 | (Am5) Lead Management |
| Glaxosmithkline, LLC. | $55.63 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $52.24 | 2023 | Uptravi, Opsumit |
| Abiomed | $51.61 | 2025 | |
| Biotronik INC. | $49.72 | 2019-2024 | Biomonitor |
| Boston Scientific Corporation | $48.59 | 2019-2024 | |
| Tactile Systems Technology INC | $45.31 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $30.22 | 2025 | |
| Daiichi Sankyo INC. | $22.79 | 2022 | |
| Irhythm Technologies, INC. | $22.64 | 2022 | |
| Heartflow, INC. | $18.89 | 2023 | Ffrct |
| Lundbeck LLC | $18.78 | 2019 | |
| Inspire Medical Systems, INC. | $18.51 | 2025 | Inspire |
| Lilly USA, LLC | $17.16 | 2022 | |
| Baxter Healthcare | $14.06 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Itamar Medical INC | $8.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.